Proteome Sciences PLC Director/PDMR Shareholding (9351V)
08 November 2017 - 11:00PM
UK Regulatory
TIDMPRM
RNS Number : 9351V
Proteome Sciences PLC
08 November 2017
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Director/PDMR Shareholding
The Company has received notification from Vulpes Life Sciences
Fund ("Vulpes") that on 6 November 2017, it purchased 20,000
ordinary shares of 1p each in the capital of the Company ("Ordinary
Shares") at 3.17p per Ordinary Share (the "Purchase"). Following
the Purchase, Vulpes has a total direct and indirect interest in
55,217,431 equivalent to 18.71% of Proteome Sciences' total issued
share capital.
The Company would also like to announce that by virtue of Martin
Diggle being a Director of both Vulpes and the Company, he now has
an interest in 55,217,431 Ordinary Shares of the Company
representing 18.71% of the issued share capital of the Company.
1. Details of the person discharging managerial responsibilities / person closely associated
a) Name Vulpes Life Sciences Fund
2. Reason for the Notification
a) Position/status PCA of Martin Diggle (NED)
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Proteome Sciences plc
b) LEI 213800Q62ICXANKU2986
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the Financial instrument, type of Ordinary Shares of 1p each
instrument
Identification code GB0003104196
b) Nature of the transaction Purchase of shares
c) Price(s) and volume(s) 20,000 Ordinary Shares at 3.17p per Ordinary Share
d) Aggregated information:
-- Aggregated volume 20,000 Ordinary Shares of 1p each purchased at 3.17p
-- Price per Ordinary Share
e) Date of the transaction 6 November 2017
f) Place of the transaction London Stock Exchange, AIM Market (XLON)
For further information:
Proteome Sciences plc
Jeremy Haigh, Chief Executive Officer
Tel: +44 (0)20 7043 2116
Ian Pike, Chief Scientific Officer
Stefan Fuhrman, Interim Finance Director
finnCap Limited (Nominated Adviser/Broker)
Geoff Nash/James Thompson Tel: +44 (0)20
7220 0500
Tony Quirke (broking)
IFC Advisory (Financial PR and IR)
Tim Metcalfe/Graham Herring/Miles Nolan Tel: +44 (0)20
3053 8671
Notes for editors:
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences is a leader in applied proteomics offering
high sensitivity, proprietary technologies and workflows for
mapping cell signalling pathways (SysQuant(R) ) and for the
discovery, validation and assay development of protein biomarkers
(TMTcalibrator(TM) ). The company has its headquarters in London,
UK, with laboratory facilities in Frankfurt, Germany from where the
PS Biomarker Services(TM) division provides outsourced proteomics
services and proprietary biomarker assays to biopharmaceutical and
diagnostics companies and to academia.
Proteome Sciences has patented a number of novel protein
biomarkers for diagnostic and treatment applications in important
areas of human therapeutics such as cancer, stroke and Alzheimer's
disease, and these are available for license.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHFSSFFAFWSELF
(END) Dow Jones Newswires
November 08, 2017 07:00 ET (12:00 GMT)
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Apr 2024 to May 2024
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From May 2023 to May 2024